WC
RMD icon

Westerkirk Capital’s ResMed RMD Stock Holding History

Westerkirk Capital’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$471K Hold
2,100
– – 0.05% 151
2025
Q4 		$506K Buy
2,100
+600
+40% +$153K 0.05% 152
2025
Q3 		$411K Sell
1,500
-200
-12% -$54.6K 0.05% 205
2025
Q2 		$439K Buy
+1,700
New +$406K 0.05% 195

Other funds holding RMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Westerkirk Capital's RMD Position: Q1 2026 in Review

Westerkirk Capital held its ResMed (RMD) position steady in Q1 2026 at 2,100 shares worth $471K. The position accounts for 0.05% of the portfolio, ranked #151.

Westerkirk Capital first reported a position in RMD in Q2 2025 and has held it in 4 quarters since. The position peaked at $506K in Q4 2025. 939 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

  • Westerkirk Capital held 2,100 shares of ResMed worth $471K as of Q1 2026.
  • Westerkirk Capital left its ResMed share count unchanged in Q1 2026.
  • ResMed made up 0.05% of Westerkirk Capital's portfolio in Q1 2026, its #151 holding.
  • Westerkirk Capital first reported a position in ResMed in Q2 2025 and has held it in 4 quarters since.
  • Westerkirk Capital's ResMed position peaked at $506K in Q4 2025.
  • 939 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Westerkirk Capital's 13F filing for Q1 2026, filed 14 May 2026.